13.03 USD
+0.20
1.56%
At close Jan 14, 4:00 PM EST
After hours
13.04
+0.01
0.08%
1 day
1.56%
5 days
0.15%
1 month
-4.68%
3 months
5.51%
6 months
10.99%
Year to date
-0.76%
1 year
79.23%
5 years
39.21%
10 years
1.48%
 

About: Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and us consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.

Employees: 92,400

0
Funds holding %
of 6,815 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 92

22% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 41

9% more capital invested

Capital invested by funds: $2.23B [Q2] → $2.44B (+$211M) [Q3]

2% more funds holding

Funds holding: 348 [Q2] → 354 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.1% less ownership

Funds ownership: 1.4% [Q2] → 1.3% (-0.1%) [Q3]

9% less call options, than puts

Call options by funds: $77.9M | Put options by funds: $85.6M

Research analyst outlook

We haven’t received any recent analyst ratings for BCS.

Financial journalist opinion

Based on 19 articles about BCS published over the past 30 days

Neutral
Business Wire
1 day ago
Barclays Bank PLC Amends Purchase Price of Certain Cash Tender Offers and Consent Solicitations
NEW YORK--(BUSINESS WIRE)--Barclays Bank PLC (the “Issuer”) announced today that, in connection with its previously announced cash tender offers (each, an “Offer”) to purchase any and all of its outstanding exchange-traded notes (the “Notes” or the “ETNs”) of four separate series (each, a “Series”) and the solicitation of consents (each, a “Consent Solicitation”) from holders of the Notes (the “Noteholders”) to amend certain provisions of the Notes with respect to each Series, it has amended th.
Barclays Bank PLC Amends Purchase Price of Certain Cash Tender Offers and Consent Solicitations
Negative
Reuters
1 day ago
Exclusive: Barclays sustainability chief exits in latest bank reshuffle
Barclays' group head of sustainability Laura Barlow has stepped down to pursue other opportunities, a spokesperson told Reuters, the latest senior reshuffle among Britain's top banks as the sector faces increased scrutiny over its climate efforts.
Exclusive: Barclays sustainability chief exits in latest bank reshuffle
Positive
Proactive Investors
1 day ago
Barclays a 'buy' with European investment banks now too cheap to ignore
UBS has increased its price target for Barclays PLC (LSE:BARC) to 360p from 350p, maintaining a 'buy' recommendation as the UK lender continues to benefit from strong growth prospects in investment banking. The Swiss group reiterated its preference for European investment banks, including Barclays and Deutsche Bank, over US counterparts such as Goldman Sachs and Morgan Stanley (NYSE:MS), citing a significant valuation discount that is "too wide to ignore.
Barclays a 'buy' with European investment banks now too cheap to ignore
Neutral
CNBC International TV
6 days ago
Market volatility expected until U.S. inauguration day, Barclays says
Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.
Market volatility expected until U.S. inauguration day, Barclays says
Positive
Seeking Alpha
1 week ago
Barclays: Set To Soar To Greater Heights
Barclays had a stellar 2024, rising over 70%, driven by a rebound in investment banking activity, strong cost controls, and higher NIMs despite falling rates thanks to structural hedges. Management's ambitious targets for income growth through to FY26 haven't been priced in, with an improved cost-to-income ratio, and plans for giant shareholder returns. Unlike some other UK banks, BCS is uniquely positioned to benefit from both sides of the rate environment due to its structural hedges and IB division, offering multiple growth catalysts.
Barclays: Set To Soar To Greater Heights
Negative
New York Post
2 weeks ago
Barclays fires over a dozen bankers, traders before Christmas — without giving them bonuses: sources
The scrooges at Barclays canned 15 Wall Street workers out of the roughly 50 it pink-slipped last month, two sources with close knowledge of the situation said.
Barclays fires over a dozen bankers, traders before Christmas — without giving them bonuses: sources
Positive
Forbes
2 weeks ago
What Drove The 70% Surge In Barclays Stock This Year?
Barclays stock (NYSE: BCS) has gained about 70% year-to-date, as compared to the 25% rise in the S&P500 over the same period. In contrast, Barclays' peer Bank of America (NYSE: BAC) is up 35% year-to-date.
What Drove The 70% Surge In Barclays Stock This Year?
Neutral
CNBC Television
2 weeks ago
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental CagriSema weight loss drug, and more.
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Positive
Seeking Alpha
3 weeks ago
Barclays: Still Trading At 0.6x 2026 Book Value
Barclays remains a high-conviction pick, outperforming peers in 2024, trading at ~0.6x 2026 TBV despite a 70% YTD increase. The bank targets a +12% RoTE by 2026, focusing on high-return UK segments and cost efficiency, driving current outperformance. Analysts projections expect Barclays to meet cost-income targets but fall short on RoTE due to lower revenue growth; current valuation reflects a discount to U.S. peers.
Barclays: Still Trading At 0.6x 2026 Book Value
Neutral
Bloomberg Markets and Finance
3 weeks ago
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest.
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Charts implemented using Lightweight Charts™